EP0921805A4 - Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations - Google Patents

Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Info

Publication number
EP0921805A4
EP0921805A4 EP97919930A EP97919930A EP0921805A4 EP 0921805 A4 EP0921805 A4 EP 0921805A4 EP 97919930 A EP97919930 A EP 97919930A EP 97919930 A EP97919930 A EP 97919930A EP 0921805 A4 EP0921805 A4 EP 0921805A4
Authority
EP
European Patent Office
Prior art keywords
melanoma
specific
cytotoxic lymphocytes
uses therefor
restricted cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97919930A
Other languages
German (de)
English (en)
Other versions
EP0921805A1 (fr
Inventor
Craig L Slingluff
Donald F Hunt
Jeffrey Shabanowitz
Andrea L Cox
Victor H Engelhard
David Kittlesen
J Binswood Avenue Skipper
Ronald C Hendrikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia UVA
University of Virginia Patent Foundation
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation filed Critical University of Virginia UVA
Publication of EP0921805A1 publication Critical patent/EP0921805A1/fr
Publication of EP0921805A4 publication Critical patent/EP0921805A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP97919930A 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations Withdrawn EP0921805A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27627 1979-04-06
US1397296P 1996-03-19 1996-03-19
US2762796P 1996-10-04 1996-10-04
PCT/US1997/004958 WO1997034613A1 (fr) 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations
US13972 2001-12-11

Publications (2)

Publication Number Publication Date
EP0921805A1 EP0921805A1 (fr) 1999-06-16
EP0921805A4 true EP0921805A4 (fr) 2002-06-26

Family

ID=26685490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97919930A Withdrawn EP0921805A4 (fr) 1996-03-19 1997-03-17 Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations

Country Status (4)

Country Link
EP (1) EP0921805A4 (fr)
AU (1) AU712820B2 (fr)
CA (1) CA2249390C (fr)
WO (1) WO1997034613A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763071B1 (fr) * 1997-05-07 2003-05-16 Centre Nat Rech Scient Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
CA2334958A1 (fr) * 1998-12-24 2000-07-06 New York Medical College Mimetiques peptidiques utiles pour traiter des maladies
EP1150708A2 (fr) * 1999-02-11 2001-11-07 Genzyme Corporation Concatomeres de peptide antigene
WO2001030847A1 (fr) 1999-10-22 2001-05-03 Aventis Pasteur Limited Molecule gp100 modifiee et ses applications
WO2001032193A1 (fr) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Peptides stimulant les lymphocytes t cytotoxiques, utilisables en prevention, traitement et diagnostic de melanome
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2001092307A2 (fr) * 2000-05-31 2001-12-06 Genzyme Corporation Composes therapeutiques pour le cancer de l'ovaire
WO2002060390A2 (fr) * 2001-01-04 2002-08-08 Yale University Induction de reponses immunitaires a des antigenes modifies a l'isoaspartyle
CN1313617C (zh) 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
US8530182B2 (en) 2007-12-05 2013-09-10 Centers For Disease Control And Prevention Viral protein quantification process and vaccine quality control therewith

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033810A2 (fr) * 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Peptides appauvris en cysteine reconnus par des lymphocytes cytotoxiques limites par a3 et leurs mises en application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860875D1 (en) * 1977-09-28 1981-10-15 Nat Res Dev Immunological preparations incorporating mhc antigens and their production
ES2172287T4 (es) * 1992-12-22 2003-04-16 Ludwig Inst Cancer Res Metodos de deteccion y tratamiento de individuos con celulas anormales que expresan los antigenos peptidicos hla-a2/tirosinasa.
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033810A2 (fr) * 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Peptides appauvris en cysteine reconnus par des lymphocytes cytotoxiques limites par a3 et leurs mises en application

Also Published As

Publication number Publication date
EP0921805A1 (fr) 1999-06-16
CA2249390C (fr) 2007-12-18
AU2424397A (en) 1997-10-10
CA2249390A1 (fr) 1997-09-25
AU712820B2 (en) 1999-11-18
WO1997034613A1 (fr) 1997-09-25

Similar Documents

Publication Publication Date Title
ZA975533B (en) Cyclosporin-containing pharmaceutical composition.
HK1017257A1 (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants.
ZA989061B (en) Medicaments.
HUP9901674A3 (en) New pharmaceutical combination
HK1027957A1 (en) Pharmaceutical composition.
AU5006097A (en) Fault-tolerant butterfly switch
DE69723848D1 (en) 3-descladinose-2,3-anhydroerythromycin-derivate
AU2764997A (en) Udp-(n)-acetyl-alpha-d-galactosamine:polypeptide (n)-acetylgalactosaminyltransferase, galnac-t3
EP0921805A4 (fr) Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations
ZA9811505B (en) Novel pharmaceutical.
AU739516C (en) Novel lantibiotic related to actagardine, and processes for the preparation and use thereof
HK1001404A1 (en) Isolated, tyrosinase derived peptides and uses thereof.
ZA974270B (en) Pharmaceutical compositions based on diclofenac.
GB2321502B (en) Turbocharger arrangement
GB9605293D0 (en) Medicaments
ZA972454B (en) Gas separation.
GB9618974D0 (en) Medicaments
ZA974052B (en) New benzothiazolinones.
AU1571299A (en) Polypeptides, polynucleotides and uses thereof
EP0935608A4 (fr) Peptides cytotoxiques
AU1110699A (en) Estra-1,3,5(10)-triene-7alpha-thioethers
ZA9610510B (en) Novel peptides, the preparation and use thereof.
GB2315981B (en) Finger ring
GB9611167D0 (en) Medicaments
AU4946297A (en) A composition comprising an immobilised, acylated peptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020515

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 14/705 A, 7C 07K 14/47 B, 7C 12N 15/11 B, 7A 61K 39/00 B

17Q First examination report despatched

Effective date: 20050405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051018